VCYT - Veracyte Inc Stock Price, Fair Value and News

$47.77+1.61 (+3.49%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VCYT Price Action

Last 7 days

0.1%

Last 30 days

31.1%

Last 90 days

51.6%

Trailing 12 Months

9.4%

VCYT RSI Chart

VCYT Valuation

Market Cap

3.8B

Price/Earnings (Trailing)

124.56

Price/Sales (Trailing)

7.63

EV/EBITDA

64.8

Price/Free Cashflow

38.45

VCYT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VCYT Fundamentals

VCYT Revenue

Revenue (TTM)

495.1M

Rev. Growth (Yr)

13.82%

Rev. Growth (Qtr)

1.31%

VCYT Earnings

Earnings (TTM)

30.3M

Earnings Growth (Yr)

26.28%

Earnings Growth (Qtr)

2.1K%

VCYT Profitability

Operating Margin

92.71%

EBT Margin

6.26%

Return on Equity

2.41%

Return on Assets

2.22%

Free Cashflow Yield

2.6%

VCYT Investor Care

Shares Dilution (1Y)

2.00%

Diluted EPS (TTM)

0.39

VCYT Alerts

7 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	463.4M	479.1M	495.1M	0
2024	375.5M	399.6M	425.3M	445.8M
2023	311.2M	328.6M	343.1M	361.1M
2022	250.6M	268.4M	283.6M	296.5M
2021	123.1M	157.5M	186.7M	219.5M
2020	122.0M	112.5M	112.7M	117.5M
2019	101.5M	108.9M	116.4M	120.4M
2018	75.6M	79.9M	85.9M	92.0M
2017	68.0M	71.7M	70.6M	72.0M
2016	51.8M	54.6M	60.9M	65.1M
2015	41.9M	45.2M	47.7M	49.5M
2014	25.0M	28.6M	32.8M	38.2M
2013	14.5M	17.1M	19.5M	21.9M
2012	4.9M	7.1M	9.4M	11.6M
2011	0	0	0	2.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Veracyte Inc

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

CEO	Mr. Marc A. Stapley
WEBSITE	veracyte.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	787

Veracyte Inc Frequently Asked Questions

What is the ticker symbol for Veracyte Inc? What does VCYT stand for in stocks?

VCYT is the stock ticker symbol of Veracyte Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Veracyte Inc (VCYT)?

As of Wed Dec 03 2025, market cap of Veracyte Inc is 3.78 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VCYT stock?

You can check VCYT's fair value in chart for subscribers.

Is Veracyte Inc a good stock to buy?

The fair value guage provides a quick view whether VCYT is over valued or under valued. Whether Veracyte Inc is cheap or expensive depends on the assumptions which impact Veracyte Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VCYT.

What is Veracyte Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, VCYT's PE ratio (Price to Earnings) is 124.56 and Price to Sales (PS) ratio is 7.63. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VCYT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Veracyte Inc's stock?

In the past 10 years, Veracyte Inc has provided 0.212 (multiply by 100 for percentage) rate of return.